Market Scenario 

Europe medical cannabis oil market was valued at US$ 905.56 million in 2023 and is projected to hit the market valuation of US$ 2,395.83 million by 2032 at a CAGR of 12.8% during the forecast period 2024–2032.

The European medical cannabis oil market is poised for substantial growth, driven by increasing patient demand and evolving regulatory landscapes. As of 2023, Germany and the UK remain the predominant forces in this market. German patients spend an average of €1,700 annually on medical cannabis products, reflecting a steady increase in consumption. The UK, with its cautious approach to full legalization, has seen a marked rise in medical cannabis prescriptions, with patients averaging €4,000 in annual expenditure. By 2028, these two countries are expected to account for 77% of all medical cannabis sales and patient numbers in Europe, underscoring their pivotal roles in the market.

Production and importation activities have kept pace with the rising demand. In 2023, the Netherlands produced over 2,500 kilograms of medical cannabis, while Italy imported approximately 3,000 kilograms. Germany continues to dominate the medical cannabis oil market, accounting for nearly 50% of all medical cannabis imports into Europe. This robust production and importation network is crucial for meeting the growing patient demand and ensuring a steady supply of medical cannabis oil across the continent.

Investment in research and development (R&D) remains a cornerstone of the European medical cannabis market. Companies have invested over €350 million in R&D initiatives in 2023, focusing on the creation of innovative products and the expansion of treatment options for patients. This investment is vital for the development of new cannabis-based therapies and improving patient outcomes. The market's expansion is further fueled by broader macroeconomic factors such as increasing healthcare expenditures, an aging population, and evolving regulatory frameworks. These elements, combined with Europe's diverse consumer base and substantial purchasing power, are set to propel the medical cannabis oil market forward. With these trends, the future outlook for medical cannabis oil in Europe is highly promising, with continued growth and development anticipated in the coming years. 

To Get more Insights,  Request A Free Sample 

Market Dynamics 

Driver: Increasing Acceptance and Legalization Across European Countries Driving Market Growth

The increasing acceptance and legalization of medical cannabis oil across Europe serve as a significant driver for medical cannabis oil market growth. As of 2023, 22 out of 44 European countries have legalized medical cannabis oil, with Germany, the UK, and Italy leading the charge. Germany, for instance, has seen its medical cannabis market grow by 50% annually since legalization in 2017, reaching a value of €150 million in 2022. The UK followed with a 300% increase in patient prescriptions from 2018 to 2023, with 15,000 patients registered for medical cannabis treatment. Italy's market has also expanded, with patient numbers doubling in the past two years, reaching over 10,000 registered users. These figures highlight a growing trend of acceptance and utilization, indicating a robust market trajectory.

The European medical cannabis oil market oil is projected to grow at a CAGR of 12.8% from 2023 until 2032. The number of registered medical cannabis patients in Europe is expected to surpass 700,000 by 2025, up from approximately 150,000 in 2023. Additionally, countries like France and Spain are conducting pilot programs, with France's program involving 3,000 patients and Spain planning to extend its trial to 1,500 patients by 2024. The rising number of clinical trials, which have increased by 60% in the last two years, further supports the expansion of the market. This growing acceptance and legalization across Europe provide a fertile ground for the medical cannabis oil market to thrive.

Trend: Growing Investment in Research and Development for Medical Cannabis Oil

A significant trend shaping the medical cannabis oil market in Europe is the growing investment in research and development (R&D). In 2022, European investments in cannabis-related R&D reached €200 million, marking a 40% increase from the previous year. Over the past five years, the number of clinical trials involving medical cannabis oil has surged by 70%, with over 200 trials conducted in 2023 alone. This trend is driven by the increasing interest in understanding the therapeutic potential of cannabis oil for various medical conditions. For instance, in the UK, government funding for cannabis research increased by 50% from 2021 to 2023, totaling £50 million.

The European Medicines Agency (EMA) has reported a 30% increase in the number of cannabis-based drug applications submitted for approval between 2020 and 2023. Additionally, private sector companies in the medical cannabis oil market have ramped up their R&D spending, with the top five cannabis firms in Europe collectively investing €100 million in 2023, a 25% increase from 2022. The number of patents filed related to medical cannabis oil has also seen a 35% rise in the past three years. This surge in R&D investment is expected to result in more innovative products entering the market, with the potential to improve patient outcomes and expand the range of treatable conditions. As the body of scientific evidence supporting the efficacy of medical cannabis oil grows, so too does its acceptance within the medical community, further fueling market growth.

Challenge: Regulatory and Supply Chain Complexities Hindering Market Expansion

Despite the promising growth, the medical cannabis oil market in Europe faces significant challenges, primarily due to regulatory and supply chain complexities. The regulatory landscape across Europe is highly fragmented, with each country having its own set of rules and regulations regarding the production, distribution, and use of medical cannabis oil. For instance, while Germany and Italy have established regulatory frameworks, other countries like Poland and Ireland are still in the nascent stages of developing their policies. This inconsistency creates barriers for companies looking to operate across multiple European markets. In 2023, it was reported that 60% of European cannabis companies faced regulatory hurdles that delayed product launches by an average of six months.

Supply chain issues further exacerbate the challenge, with 70% of European medical cannabis oil suppliers experiencing disruptions in 2022 due to stringent import/export controls and quality assurance requirements. The European cannabis oil market saw a 20% shortfall in supply in 2023, largely due to these regulatory bottlenecks. Additionally, 50% of European countries reported a lack of sufficient infrastructure to support the cultivation and processing of medical cannabis, leading to reliance on imports. This dependency has caused price volatility, with the average cost of medical cannabis oil fluctuating by 15% over the past year. Addressing these regulatory and supply chain challenges is crucial for the sustainable growth of the medical cannabis oil market in Europe.

Segmental Analysis 

By Derivatives 

Based on derivatives, the Europe medical cannabis oil market is led by Cannabidiol (CBD) with revenue share of over 82.82%. The dominance of CBD is primarily driven by a favorable legal and regulatory environment, which has set the stage for rapid market expansion. The European Union's regulatory framework ensures product safety and quality, fostering consumer trust and market growth. A pivotal moment came in 2020 when the Court of Justice of the European Union (CJEU) declared that CBD is not a narcotic, further legitimizing its use and sale. This ruling, combined with country-specific policies like Switzerland's liberal stance on the sale of hemp flowers, has solidified CBD's market leadership in the region. The CBD segment is projected to grow at a CAGR of 12.34% from 2024 to 2032, reaching USD$2.02 billion by 2032. Additionally, the European CBD market is expected have over 50 million users by 2026, underscoring its significant penetration.

Consumer trends and preferences have also played a crucial role in CBD's dominance in the Europe medical cannabis oil market. The primary driver of CBD consumption is its perceived health benefits, including pain relief, anxiety reduction, and improved sleep quality, which have gained heightened awareness during the pandemic. The market's diverse product offerings, from edibles and oils to skincare products, cater to a wide array of consumer needs and are easily accessible through the rise of e-commerce. The demand for natural and organic products in Europe has further bolstered CBD's popularity. Economic factors such as Europe's relatively steady consumer wealth and progressive population have supported market growth. The prevalence of CBD use is notably higher among younger adults, driving consumption rates. However, challenges like regulatory uncertainty, shipping restrictions, and product mislabeling persist. Despite these barriers, the European CBD market's robust growth trajectory, evidenced by significant investments like the €118 million in cannabis startups across the EU, showcases its dominance in the medical cannabis oil sector.

By Source 

Based on source, the natural source is dominating the market with over 92.21% market share. The dominance of natural source in the Europe medical cannabis oil market can be attributed to several factors, including regulatory changes, increasing acceptance, and the therapeutic potential of cannabis-derived products. One of the primary drivers is the progressive legalization and regulation of medical cannabis across various European countries. For instance, Germany, a leading market, saw sales of medical marijuana reach an estimated US$450 million in 2023, reflecting a robust demand. Additionally, the European market has diversified significantly, with products ranging from cannabis oil to high-potency extracts and edibles, catering to a wide array of medical needs. This diversification has been supported by a growing body of research highlighting the efficacy of cannabis oil in treating conditions such as epilepsy, multiple sclerosis, and chronic pain. Moreover, countries like Switzerland have initiated trials for legal cannabis sales, indicating a broader trend towards acceptance and regulation. 

Several factors have enabled the growth of natural source in Europe medical cannabis oil market. Wherein, the regulatory landscape has become more favorable, with countries like Germany leading in sales and others like Switzerland conducting legal trials. This regulatory support has been crucial in legitimizing the use of cannabis oil for medical purposes. The increasing body of scientific evidence supporting the therapeutic benefits of cannabis oil has also played a significant role. Studies have shown its effectiveness in managing symptoms of advanced cancer, epilepsy, and other chronic conditions, which has led to higher acceptance among healthcare professionals and patients alike. The economic potential of the cannabis market has attracted significant investment, driving innovation and product development. 

By Application 

By application, the pain management segment is leading the market with revenue share of over 26.46% in 2023 and is projected to keep growing at the highest CAGR of 13.56%. The increasing demand for medical cannabis oil market for pain management across Europe can be attributed to legislative changes, growing awareness, and clinical evidence supporting its efficacy. Many European countries have begun to liberalize their cannabis laws, allowing for wider accessibility and prescription of medical cannabis oil. This legal shift is a response to the mounting body of research demonstrating the benefits of cannabis oil in managing chronic pain, a condition that affects millions across the continent. Studies have shown that cannabis oil can effectively reduce pain intensity and improve the quality of life for patients suffering from conditions like arthritis, multiple sclerosis, and cancer-related pain. Moreover, traditional pain management options, such as opioids, have come under scrutiny due to their addictive potential and adverse side effects, making cannabis oil an attractive alternative.

Germany, one of the largest medical cannabis oil markets in Europe, reported that over 1.2 million medical cannabis prescriptions were issued in 2023, with a significant portion being for pain management. The United Kingdom saw a notable increase in patient registrations for medical cannabis, with over 10,000 new patients in the first half of 2023 alone, many of whom sought treatment for chronic pain. In Italy, the national health service expanded its coverage to include medical cannabis oil, leading to a surge in demand, with pharmacies dispensing over 200 kilograms of cannabis oil in the first quarter. Additionally, Spain's patient registry indicated that out of 50,000 registered medical cannabis users, the majority cited pain relief as their primary reason for use. France's pilot program for medical cannabis, which includes 3,000 patients, reported that a substantial number of participants experienced significant pain reduction, further validating the therapeutic potential of cannabis oil. These statistics underscore the growing acceptance and reliance on medical cannabis oil as a viable pain management solution across Europe.

By End Users 

The pharmaceutical industry is the leading consumer of medical cannabis oil market in Europe with market share of over 51% due to its robust infrastructure for research, development, and distribution of cannabis-based medications. This dominance is driven by the industry's ability to conduct extensive clinical trials, which provide the necessary evidence to gain regulatory approval and the trust of healthcare professionals. For example, GW Pharmaceuticals' Epidiolex, a cannabis-derived medication for severe epilepsy, has been approved by the European Medicines Agency (EMA), highlighting the industry's capability to meet stringent quality and safety standards. Additionally, the increasing diversity of cannabis products, including high-potency extracts and oils, has expanded the therapeutic applications of medical cannabis, further driving pharmaceutical interest and investment. 

Several recent findings underscore the pharmaceutical industry's leading role in the medical cannabis oil market. In 2023, the European market saw a significant increase in the number of cannabis-based pharmaceutical products, with over 50 new products entering the market. The number of clinical trials involving medical cannabis in Europe has also risen sharply, with over 200 trials registered in the past year alone. Germany, one of the largest markets for medical cannabis in Europe, reported that over 100,000 patients were prescribed medical cannabis oil in 2023. Furthermore, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) noted that the treatment demand for cannabis-related conditions has increased, with over 350 treatment entries per 100,000 adults. Lastly, the European pharmaceutical industry's spending on research and development has reached new heights, with billions of euros invested annually in developing new cannabis-based therapies. These factors collectively highlight the pharmaceutical industry's pivotal role in the European medical cannabis oil market.

 To Understand More About this Research:  Request A Free Sample 

Country Analysis 

Germany contributes over 59.15% revenue to the Europe medical cannabis oil market. Germany has recently made significant strides in the legalization and regulation of cannabis with the implementation of the Cannabis Act on April 1, 2024. This new law permits adults aged 18 and older to possess up to 25 grams of cannabis for private consumption and cultivate up to three cannabis plants at home. The act also allows members of cultivation associations to grow, distribute, and receive cannabis. However, the German Medical Association has raised concerns about potential mental health risks for young people. Additionally, Germany imported approximately 20.8 tons of medical cannabis flowers in 2022. The hemp segment dominated the market with an 85.8% revenue share in 2023, reflecting the increasing consumer demand for high-quality cannabis products, including oils.

Germany has been a leader in the Europe medical cannabis oil market, supported by a regulatory framework that allows for the legal use of medical cannabis under certain conditions, covered by health insurance for eligible patients. The number of prescriptions for medical cannabis is on the rise, reflecting its growing acceptance as a natural remedy for various health conditions. The liberalization of cannabis laws has led to an increase in domestic cultivation, reducing reliance on imports and supporting local producers. This shift is crucial for the sustainability and growth of the cannabis market in Germany. As of 2023, Germany had approximately 100,000 registered medical cannabis patients, and the domestic market for medical cannabis was worth EUR 200 million. Germany's strong economy and high purchasing power have contributed to the growth of the cannabis market, allowing consumers to explore alternative healthcare options, such as medical cannabis, further driving market expansion. 

Top Players in Europe Medical Cannabis Oil Market 

• Aurora Cannabis Inc.
• Bedrocan
• Biocann
• BIOTA Biosciences LLC
• Cannamedical
• Mary Jane CBD
• Sanity Group GmbH
• Tilray
• Valcon Medical
• Other Prominent Players

Market Segmentation Overview:

By Derivatives

• Cannabidiol (CBD)
• Tetrahydrocannabinol (THC)
• Cannabicyclol (CBL)
• Cannabichromene (CBC)
• Others

By Source

• Natural
• Synthetic

By Application

• Alzheimer's Disease
• Appetite Loss
• Cancer
• Inflammatory Bowel Diseases
• Autism
• Mental Health Conditions
• Multiple Sclerosis
• Pain Management
• Nausea
• Muscle Spasms
• Depression and Sleep Disorders
• Others

By Route of Administration

• Oral Solutions and Capsules
• Vaporizers
• Topicals
• Others

By End User

• Pharmaceutical Industry
• Research and Development Centers
• Homecare Setting
• Hospitals
• Rehab Centers

By Distribution Channel

• B2B
• B2C

By Country

• The UK
• Germany
• The Netherlands
• Italy
• Spain
• Poland
• Rest of Europe